Pillsbury Advises Thyme Care on Series E Funding Round Totaling More Than $125 Million

Morgan Health led the round, with participation from strategic healthcare investors Humana and CVS Health Ventures and institutional investors AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures and a16z Bio + Health.

The financing brings together investors from across the cancer care ecosystem, including leading national payers, community oncology practices, health systems and organizations focused on employer-sponsored health care.

In conjunction with the Series E financing, Thyme Care is establishing Thyme Companies, a newly formed parent entity that will build a portfolio of independent oncology businesses focused on addressing persistent barriers to better cancer care. Grounded in data, enabled by technology and built on trusted partnerships, Thyme Companies aims to take on oncology’s most complex challenges.

Click here to learn more.

The Pillsbury deal team included Emerging Companies and Venture Capital partner Ron Fleming, counsel Taylor O’Toole and associate Sarah Konnerth, Tax partner Nora Burke, Executive Compensation & Benefits partner Jessica Lutrin and senior law clerks Claudia Hanover and Lauryn Holliday.